echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Enesi Pharmaceuticals of the United Kingdom is associated with Sementis, an Australian biotechnology company

    Enesi Pharmaceuticals of the United Kingdom is associated with Sementis, an Australian biotechnology company

    • Last Update: 2021-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Enesi Pharmaceuticals of the United Kingdom has signed an agreement with an Australian biotechnology company to develop a solid dose version of the latter's peanut low-dose allergy vaccine and its chikungi/Zika vaccine candidate.
    vaccine is being evaluated through Enesi Pharmaceutical Group's ImpalVax technology, needleless solid dose injections to assess the use of the vaccine, and device technology for intrauteric vaccination.
    Sementis' research peanut hypoallery vaccine has completed a proof-of-concept study, according to the organization's press release, "provides compelling evidence that it can provide a permanent treatment for peanut allergies."
    believes that more than 7 million people in the United States, Europe and Japan suffer from severe peanut allergies, and that a vaccine that supports Impalvax could provide "an easy and effective way to cure peanut allergies on large scales, especially for young patients who may be averse to needles and traditional injections."
    Sementis, a single vector vaccine for chikungi/Zika virus infection, also showed promising results in concept validation studies in mice.
    "Activate ImplaVax products using the Sementis SCV chikungunya/Zika vaccine provides the potential for long-lasting immunity and can remain effective in a variety of situations," the company said. "Working with our ImpalVax needleless device to develop solid dose versions of these vaccines offers the potential to deliver powerful and effective products that address major global health challenges," said David Hipkiss, Ceo of Enesi. "We are seeing growing interest in the vaccine and public health industries in all regions, depending on the potential benefits that ImpaVax can offer to improve vaccination." "We are very confident that Impravax technology will work with our vaccine vector technology to reduce or even eliminate the cryo-chain environment that relies on maintaining from manufacturing to care points, and may provide long-term stability for our vaccines." Dr Paul Howley, chief executive of Enesi, added.
    In addition, Enesi's technology may not require trained health care providers to manage our vaccines because they do not require injections. "We will test this technology with our infectious disease vaccine and one of our allergy vaccines, Candide, and if proven, ImpraVax technology will be suitable for all Smallis vaccines covering infectious diseases, allergies and cancers.
    terms of the deal, Enesi will develop solid dose injections based on vaccines provided by Sementis, which will conduct safety and immunogenicity tests, as well as preclinical development. Financial details have not been disclosed. (This web article)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.